Articles: function.
-
Infectious Disease Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The etiology of bronchiectasis is varied with abnormal host defenses being one of the causes. We report the case of a 49-year-old male presenting with recurrent pneumonias. Imaging studies revealed bronchiectasis. Work up for bronchiectasis showed low immunoglobulin levels consistent with common variable immunodeficiency (CVID). The aim of this case report is to heighten awareness among physicians for the possibility of immunoglobulin deficiency in patients presenting especially with bronchiectasis, recurrent infections and sinus disease. ⋯ Among the various etiologies of bronchiectasis, the potentially treatable ones like CVID should never be missed. Appropriate and early institution of treatment can potentially improve survival, prevent deterioration of lung function and improve quality of life.Reference #1: Busse PJ, Farzan S, Cunningham-Rundles C, "Pulmonary complications of common variable immunodeficiency" Ann Allergy Asthma Immunol. 2007;98(1):1Reference #2: Park JH, Levinson AI,"Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)" Clin Immunol. 2010;134(2):97DISCLOSURE: The following authors have nothing to disclose: Khalid Sherani, Hineshkumar Upadhyay, Abhay Vakil, Kelly Cervellione, Craig ThurmNo Product/Research Disclosure Information.
-
Cardiovascular Disease PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The risk of stroke associated to the various means of cardiac stimulation is still limited and offers only tendencies. It is only known that patients with sinus node dysfunction are in risk of stroke and suggest that ventricular demand pacemakers do not offer protection against this risk. ⋯ The following authors have nothing to disclose: Elieusa Sampaio, Roque Aras Júnior, José Alberto da Matta, Cristiano Macedo, Márcia Maria Oliveira, Ubiratan dos Santos Júnior, Sérgio CâmaraNo Product/Research Disclosure Information.
-
COPD Epidemiology & Physiology PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Purpose: Canada's fourth leading cause of death is chronic lower respiratory diseases including chronic obstructive pulmonary disease (COPD) and pneumonia. COPD is a leading cause of death worldwide and is frequently underdiagnosed and untreated. The objective of this paper is to determine the prevalence of airway obstruction (AO) and associated risk factors in farming and non-farming rural populations in Saskatchewan. ⋯ The following authors have nothing to disclose: Chandima Karunanayake, Josh Lawson, Donna Rennie, Louise Hagel, James Dosman, Punam PahwaNo Product/Research Disclosure Information.
-
Comorbidities of OSA PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The cardiovascular complications(CVC) are the important causes of mortality/morbidity in OSAS. Hypoxia, vascular endothelial dysfunction and hypercoagulability are some of the pathophysiological mechanisms. In presence of hypoxia, hematocrit increases to maintain constant delivery of oxygen to the tissue. Hyperviscosity from increased hematocrit is one of the stimuli for atherosclerotic process. Mean platelet volume(MPV) is an indicator of platelet activation and was found to be an indicator for atherosclerosis. We investigated correlation between the hematocrit and MPV levels with the severity and response of OSAS to the CPAP therapy. ⋯ The following authors have nothing to disclose: Gülcan Çetin, Elif Kupeli, Serife Savas Bozbas, Füsun Öner EyüboğluNo Product/Research Disclosure Information.
-
For stroke prevention in patients with atrial fibrillation and other indications new oral anticoagulants have been developed. These drugs are direct anticoagulants in contrast to the indirectly acting vitamin-K antagonists, which are used for decades as the only available drugs. ⋯ However, to transfer the benefit from the large scale studies to the real world conditions, physicians have to get clinical experience in using the new drugs. Especially drug interactions, impaired renal function and periinterventional bridging need special attention to ensure transfer of the new drugs benefits to daily life treatment.